Low Dose PPARγ Agonist Treatment Started in Mid-Life Extends Median Lifespan by 11% in Mice

Researchers here note a modest life extension in mice resulting from long-term treatment with low doses of a PPARγ agonist drug, started in mid-life. This is thought to be an adjustment that acts to suppress inflammation and improve insulin metabolism, both strongly connected to the way in which cellular metabolism determines pace of aging. The size of the effect in mice is small enough to think that it would have little effect on life span in our species, however. Effects derived from this sort of metabolic adjustment have a much larger impact on life span in short-lived species than they do in long-lived species, as most of the relevant stress response mechanisms connecting metabolism to environmentally induced variations in the pace of aging evolved as a part of the life-extending response to calorie restriction. A seasonal famine is a long time to a mouse, not so long to a human, so only the mouse evolves a sizable gain in life span when these stress response mechanisms are trigger.

Aging leads to a number of disorders caused by cellular senescence, tissue damage, and organ dysfunction. It has been reported that anti-inflammatory and insulin-sensitizing compounds delay, or reverse, the aging process and prevent metabolic disorders, neurodegenerative disease, and muscle atrophy, improving healthspan and extending lifespan. Here we investigated the effects of PPARγ agonists in preventing aging and increasing longevity, given their known properties in lowering inflammation and decreasing glycemia.

Our molecular and physiological studies show that long-term treatment of mice at 14 months of age with low doses of the PPARγ ligand rosiglitazone (Rosi) improved glucose metabolism and mitochondrial functionality. These effects were associated with decreased inflammation and reduced tissue atrophy, improved cognitive function, and diminished anxiety- and depression-like conditions, without any adverse effects on cardiac and skeletal functionality. Furthermore, Rosi treatment of mice started when they were 14 months old was associated with an 11% median lifespan extension.

A retrospective analysis of the effects of the PPARγ agonist pioglitazone (Pio) on longevity showed decreased mortality in patients receiving Pio compared to those receiving a PPARγ-independent insulin secretagogue glimepiride. Taken together, these data suggest the possibility of using PPARγ agonists to promote healthy aging and extend lifespan.

Link: https://doi.org/10.1111/acel.13267

Comments

This brings us back to the interesting studies on the anti-aging effects of low dose Pioglitazone. Why is metformin in getting the attention when Pioglitazone does just this. Youthful Dermal fat retention is one of the most interesting for those of us prone to bruising or saggy skin. 7.5 mg per day?

Posted by: August33 at December 1st, 2020 8:56 PM

I wonder if this has implications for other PPARγ agonists, like telmisartan

Posted by: Matt at December 7th, 2020 5:12 PM

https://www.researchgate.net/publication/321629998_Pioglitazone_attenuates_aging-related_disorders_in_aged_apolipoprotein_E_deficient_mice

" Moreover, accompanied with up-regulation of PPARγexpression, Piog hadobviously increased the mRNA levels of anti-aging genes Sirtuin1 and Klotho, decreased the p53 protein level,and altered the expression of several genes involving cholesterol excretion, TG biosynthesis and inflammation inthe liver. In conclusion, Piog treatment is effective to modulate the oxidative and inflammatory status, cellsenescence, and lipid metabolism, contributing to attenuate several aging-related disorders in the aged apoE-/-mice, thereby maybe a promising protective therapy of aging and age-related disease"

Posted by: august33 at January 15th, 2021 10:20 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.